Author(s): Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S,
Abstract Share this page
Abstract Preclinical and clinical findings suggest that tumor-specific immune responses may be responsible--at least in part--for the clinical success of therapeutic regimens that rely on immunogenic cell death (ICD) inducers, including anthracyclines and oxaliplatin. The molecular pathways whereby some, but not all, cytotoxic agents promote bona fide ICD remain to be fully elucidated. Nevertheless, a central role for the endoplasmic reticulum (ER) stress response has been revealed in all scenarios of ICD described thus far. Hence, components of the ER stress machinery may constitute clinically relevant druggable targets for the induction of ICD. In this review, we will summarize recent findings in the field of ICD research with a special focus on ER stress mechanisms and their implication for cancer therapy. Copyright © 2013 Elsevier Ltd. All rights reserved.
This article was published in Cytokine Growth Factor Rev
and referenced in Journal of Clinical & Cellular Immunology